M

PTO/SB/05 (2/98)

Approved for use through 09/30/2000. OMB 0651-0032

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

12

UTILITY TRANSMITTAL PTO SB 05, 9/99, (1/1)

UTILITY PATENT APPLICATION TRANSMITTAL

Please type a plus sign (+) inside this box →

Signature 5 4 1

Attorney Docket No.

PC11026AJAK

First Named Inventor or Application Identifier

Stephanie K. Hall

Title

Methods and Reagents for Detecting Increased Risk of Developing an Inflammatory Disorder

Express Mail Label No.

EL911725504US

(Only for new nonprovisional applications under 37C.F.R. §1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO: **Box Patent Application** Washington, DC 20231 See MPEP chapter 600 concerning utility patent application contents. Microfiche Computer Program (Appendix) 6. *Fee Transmittal Form (e.g., PTO/SB/17) 1. (Submit an original, and a duplicate for fee processing) Nucleotide and/or Amino Acid Sequence Submission 7. (if applicable, all necessary) 2. Specification [Total Pages 29 (preferred arrangement set forth below) Descriptive title of the Invention Computer Readable Copy Cross References to Related Applications Paper Copy (identical to computer copy) b. Statement Regarding Fed sponsored R&D Reference in Microfiche Appendix Statement verifying identity of above copies c. **ACCOMPANYING APPLICATION PARTS** Background of the Invention Brief Summary of the Invention Assignment Papers (cover sheet & document(s)) 8. Brief Description of the Drawings (if filed) Power of Attorney 37 C.F.R. §3.73(b) Statement **Detailed Description** 9. Claim(s) (when there is an assignee) Abstract of the Disclosure English Translation Document (if applicable) 10. 14 Copies of IDS Information Disclosure 11 Drawing(s) (35 U.S.C. 11.3)[Total sheets Statement (IDS)/PTO-1449 Citations T.] Oath or Declaration Total pages 12. Preliminary Amendment Return Receipt Postcard (MPEP 503) Ň Newly executed (original or copy) 13. (Should be specifically itemized) Copy from a prior application (37 CFR Statement filed in prior application, Status still proper and desired (for continuation/divisional with Box 17 completed) Statement(s) (PTO/SB/09-12) [Note Box 5 below] **DELETION OF INVENTOR(S)** Certified Copy of Priority Document(s) 15 Signed statement attached deleting (if foreign priority is claimed) inventor(s) named in the prior application, see 37 C.F.R. §§1.63(d)(2) and 1.33(b). Other: Priority Claim Incorporation By Reference (useable if Box 4b is checked) 5. The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered to be part of the disclosure of the accompanying application and is hereby incorporated by reference therein. *NOTE FOR ITEMS 1 & 14: IN ORDER TO BE ENTITLED TO PAY SMALL ENTITY FEES, A SMALL ENTITY STATEMENT IS REQUIRED (37 C.F.R. § 1.27), EXCEPT IF ONE FILED IN A PRIOR APPLICATION IS RELIED UPON (37 C.F.R. § 1.28). If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment: of prior application No: _ Continuation-in-part (CIP) Divisional Continuation Group/Art Unit: Prior application information: Examiner CORRESPONDENCE ADDRESS 18. (Insert Customer No. or Attach bar code label here) Correspondence address below Customer Number or Bar Code Label Gregg C. Benson Name Address Pfizer Inc. Patent Department, MS 4159, Eastern Point Road Address Zip Code 06340 State Groton City 1-(860)-441-5221 1-(860)-441-4901 Fax United States Of America Telephone Country Registration No. (Attorney/Agent) 40,049 Jennifer A. Kispert NAME (Print/type)

PTO/SB/17(2/98) Approved for use through 09/30/2000. U.S. DEPARTMENT OF COMMERCE

-		OMB 0651-0032 Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Complete if Known					
		Application Number To be assigned					
FEE TRANSMITTAL							
	Filing Da	Filing Date			Herewith		
Patent fees are subject to annual revision on October 1.		First Named Inventor			Stephanie K. Hall		
These are the fees effective October 1,. 2001. Small Entity payments must be supported by a small entity statement,		Examiner Name			To be assigned		
otherwise large entity fees must be paid. See Forms PTO/SB/09-12.		Group/Art Unit			To be assigned		
See 37 C.F.R. §§ 1.27 and 1.28. Total Amount of Payment (\$)740.00		Attorney Docket No.			PC11026AJAK		
Total Amount of Payment (\$)740.00 METHOD OF PAYMENT (check one)				FEE CA	LCULATION (continued)		
		3. ADDITIONAL FEES					
The commissioner is hereby authorized to charge indicated fees and credit any over payments to:		ntity		Entity			
Deposit Account 16-1445	Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description F	ee Paid	
Number 10-1443							
Deposit Account Pfizer, Inc.	105	130	205	65	Surcharge – late fee or oath		
Name Prizer, Inc.							
_		50	227	25	Surcharge-late provisional filing fee or cover sheet		
Charge Any Additional 37 Fee Required Under Charge the Issue Fee Set in 37 C.F.R. § 1.1.8 at the Mailing	139	130	139	130	Non-English specification		
C.F.R. §§ 1.1.6 and 1.17. of the Notice of Allowance.		2,520	147	2,520	For filing a request for reexamination		
	147	920*	112	920*	Requesting publication of SIR prior to		
2. Payment Enclosed:	112				Examiner action Requesting publication of SIR after		
Check Money Order Other	113	1,840*	113	1,840*	Examiner action		
FEE CALCULATION	115	110	215	55	Extension for reply within first month		
1. BASIC FILING FEE	116	400	216	200	Extension for reply within second month		
71 	117	920	217	460	Extension for reply within third month		
ਇੰਗਾe Entity Small Entity Fee: Fee Fee Fee Description Fee Paid	118	1,440	218	720	Extension for reply within fourth month		
Coffe (\$) Code (\$) 101 740 201 370 Utility filing fee 740.00	128	1,960	228	980	Extension for reply within fifth month		
9	119	320	219	160	Notice of Appeal		
106 330 206 165 Design filing fee 107 510 207 255 Plant filing fee	120	320	220	160	Filing a brief in support of an appeal		
108 740 208 370 Reissue filing fee	121	280	221	140	Request for oral hearing		
100 740 208 370 Reissue filing fee	138	1,510	138	1,510	Petition to institute a public use proceeding		
740.00	140	110	240	55	Petition to revive - unavoidable		
SUBTOTAL (1) (\$) 740.00 2. EXTRA CLAIM FEES	141	1,280	241	640	Petition to revive - unintentional		
Extra Fee from	142	1,280	242	640	Utility issue fee (or reissue)		
Claims below Fee Paid	,			230	Design issue fee		
Total Claims 16 -20**= 0 X 0 = 0	143	460	243		•		
Independent 3 - 3**= 0 X 0 = 0	144	620	244	310	Plant issue fee		
Multiple Dependent =	122	130	122	130	Petitions to the Commissioner		
** or number previously paid, if greater; For Reissues, see below	123	50	123	50	Petitions related to provisional applications		
Large Entity Small Entity Fee Fee Fee Fee Fee Description	126	180	126	180	Submission of Information Disclosure		
Code (\$) Code (\$) 103 18 203 9 Claims in excess of 20	581	40	581	40	Statement Recording each patent assignment per		
102 84 202 42 Independent claims in excess of 3	146	740	246	370	property (times number of properties) Filing a submission after final rejection		
104 280 204 140 Multiple dependent claim, if not paid	149	740	249	370	(37 ČFR 1.129(a)) For each additional invention to be		
	Other Fee (specify)			examined (37 CFR 1.129(b))			
original patent 110 18 210 9 **Reissue claims in excess of 20 and	Other Fee (specify)						
over original patent SUBTOTAL (2) (\$) 0	*Reduce	ed by Ba	sic Filing	Fee Paid	SUBTOTAL (3) (\$)	0	
SUBMITTED BY					Complete (if Applicable)		
Type or Printed Name Jennifer A. Kispert					Reg. Number 40,049		
Signature Settings A Major	Date		12	2101	Deposit Account 16-1445 User ID		

PATENT	APPLICATION	SERIAL	NO.	
	ANT DIOLITICA.	~		

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FEE RECORD SHEET

01/03/2002 EHAILE1 00000017 161445 10032242 01 FC:101 740.00 CH